VG Life Sciences Inc. (VGLS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.53 Million USD | -219.63% |
| 2022 | 2.11 Million USD | 270.53% |
| 2021 | -1.24 Million USD | 14.76% |
| 2020 | -1.45 Million USD | -442.09% |
| 2019 | -268.43 Thousand USD | 0.0% |
| 2018 | -268.43 Thousand USD | 0.0% |
| 2017 | -268.43 Thousand USD | 87.1% |
| 2016 | -2.08 Million USD | 0.0% |
| 2014 | -8.94 Million USD | -5.34% |
| 2013 | -8.49 Million USD | -123912.27% |
| 2012 | -6850.63 USD | 0.0% |
| 2006 | -18.84 Million USD | -299.95% |
| 2005 | -4.71 Million USD | 25.99% |
| 2004 | -6.36 Million USD | -43.26% |
| 2003 | -4.44 Million USD | -150.06% |
| 2002 | -1.77 Million USD | -31.02% |
| 2001 | -1.35 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -17.64 Thousand USD | -100.73% |
| 2024 Q1 | 2.42 Million USD | 196.69% |
| 2023 Q1 | -16.02 Thousand USD | 69.25% |
| 2023 Q2 | -6453.00 USD | 59.74% |
| 2023 Q4 | -2.5 Million USD | -77343.78% |
| 2023 Q3 | -3234.00 USD | 49.88% |
| 2023 FY | -2.53 Million USD | -219.63% |
| 2022 Q3 | -3923.00 USD | 0.0% |
| 2022 Q1 | -2250.00 USD | 35.71% |
| 2022 FY | 2.11 Million USD | 270.53% |
| 2022 Q4 | -52.12 Thousand USD | -1228.63% |
| 2021 FY | -1.24 Million USD | 14.76% |
| 2021 Q4 | -3500.00 USD | 99.65% |
| 2021 Q3 | -1 Million USD | -520.59% |
| 2021 Q2 | -161.13 Thousand USD | 0.0% |
| 2020 FY | -1.45 Million USD | -442.09% |
| 2019 FY | -268.43 Thousand USD | 0.0% |
| 2018 FY | -268.43 Thousand USD | 0.0% |
| 2017 FY | -268.43 Thousand USD | 87.1% |
| 2016 FY | -2.08 Million USD | 0.0% |
| 2015 Q3 | -1.26 Million USD | 30.96% |
| 2015 Q2 | -1.83 Million USD | 15.94% |
| 2015 Q1 | -2.17 Million USD | -99.61% |
| 2014 Q1 | -2.7 Million USD | 12.13% |
| 2014 Q2 | -1.99 Million USD | 26.11% |
| 2014 Q3 | -1.75 Million USD | 12.37% |
| 2014 FY | -8.94 Million USD | -5.34% |
| 2014 Q4 | -1.09 Million USD | 37.7% |
| 2013 Q2 | -461.3 Thousand USD | -19694.02% |
| 2013 Q3 | -1.54 Million USD | -235.79% |
| 2013 Q4 | -3.07 Million USD | -98.66% |
| 2013 Q1 | -2330.50 USD | 0.0% |
| 2013 FY | -8.49 Million USD | -123912.27% |
| 2012 FY | -6850.63 USD | 0.0% |
| 2007 Q1 | 88.55 Thousand USD | 104.51% |
| 2007 Q2 | -1.01 Million USD | -1240.68% |
| 2007 Q3 | -1.01 Million USD | -0.71% |
| 2006 Q2 | -1.92 Million USD | 76.04% |
| 2006 FY | -18.84 Million USD | -299.95% |
| 2006 Q4 | -1.96 Million USD | -183.95% |
| 2006 Q3 | -691.51 Thousand USD | 64.06% |
| 2006 Q1 | -8.03 Million USD | -399.08% |
| 2005 Q1 | -1.18 Million USD | 22.78% |
| 2005 Q3 | -640.96 Thousand USD | 43.92% |
| 2005 Q2 | -1.14 Million USD | 3.41% |
| 2005 Q4 | -1.6 Million USD | -151.05% |
| 2005 FY | -4.71 Million USD | 25.99% |
| 2004 FY | -6.36 Million USD | -43.26% |
| 2004 Q1 | -1.77 Million USD | 14.39% |
| 2004 Q2 | -2.68 Million USD | -51.38% |
| 2004 Q3 | -945.9 Thousand USD | 64.82% |
| 2004 Q4 | -1.53 Million USD | -62.0% |
| 2003 FY | -4.44 Million USD | -150.06% |
| 2003 Q4 | -2.07 Million USD | -159.23% |
| 2003 Q1 | -29.84 Thousand USD | 91.41% |
| 2003 Q3 | -800.43 Thousand USD | 47.95% |
| 2003 Q2 | -1.53 Million USD | -5052.85% |
| 2002 Q3 | -869.1 Thousand USD | -217.65% |
| 2002 Q2 | -273.6 Thousand USD | 4.6% |
| 2002 Q1 | -286.79 Thousand USD | 73.68% |
| 2002 FY | -1.77 Million USD | -31.02% |
| 2002 Q4 | -347.33 Thousand USD | 60.04% |
| 2001 FY | -1.35 Million USD | 0.0% |
| 2001 Q4 | -1.08 Million USD | -14501.78% |
| 2001 Q3 | -7462.00 USD | 66.39% |
| 2001 Q1 | -37.32 Thousand USD | 10.01% |
| 2001 Q2 | -22.2 Thousand USD | 40.51% |
| 2000 Q4 | -41.46 Thousand USD | 33.65% |
| 2000 Q3 | -62.49 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -89.47% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 63.765% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 104.776% |
| Nascent Biotech, Inc. | -2.08 Million USD | -21.199% |
| Rebus Holdings, Inc. | -1.02 Million USD | -148.063% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 103.885% |
| Qrons Inc. | -789.34 Thousand USD | -220.549% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -300.098% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 95.958% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -508.995% |
| Skye Bioscience, Inc. | -37.64 Million USD | 93.279% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 96.625% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 61.524% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -825.468% |
| SQZ Biotechnologies Company | -79.46 Million USD | 96.816% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 12.521% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -38.984% |
| Mesoblast Limited | -87.95 Million USD | 97.123% |
| Marizyme, Inc. | -65.34 Million USD | 96.128% |
| Genus plc | 7.9 Million USD | 132.028% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 76.769% |
| Pharming Group N.V. | -10.54 Million USD | 76.012% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -16.611% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 31.804% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 71.39% |
| ContraFect Corporation | -65.15 Million USD | 96.116% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 48.215% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -46.473% |
| IMV Inc. | -36.48 Million USD | 93.065% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 68.606% |
| MultiCell Technologies, Inc. | -380.07 USD | -665631.839% |
| ONE Bio Corp. | 8.67 Million USD | 129.162% |
| Accustem Sciences Inc. | -3.74 Million USD | 32.462% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 95.105% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -99.683% |
| Q BioMed Inc. | -2.05 Million USD | -23.301% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 32.219% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -6.274% |
| Biomind Labs Inc. | -1.21 Million USD | -108.368% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 95.764% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 18.426% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 67.984% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -29.806% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -16795.346% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 84.058% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 56.504% |
| GB Sciences, Inc. | -1.36 Million USD | -85.818% |
| Alpha Cognition Inc. | -13.77 Million USD | 81.628% |
| HST Global, Inc. | -146.21 Thousand USD | -1630.557% |
| CSL Limited | 2.64 Billion USD | 100.096% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -44.192% |
| Halberd Corporation | -79.67 Thousand USD | -3075.67% |
| Enzolytics Inc. | -2.17 Million USD | -16.235% |
| Agentix Corp. | -1.37 Million USD | -84.124% |
| Resverlogix Corp. | -3.61 Million USD | 29.91% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 20.218% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.142% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2681.885% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 136.54% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 36.314% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 16.387% |
| AVAX Technologies, Inc. | -6.41 Million USD | 60.549% |
| Zenith Capital Corp. | -10.59 Million USD | 76.121% |
| Genscript Biotech Corporation | -95.47 Million USD | 97.35% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -10786.529% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 38.97% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -4086.336% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -26.19% |
| Kadimastem Ltd | -3.3 Million USD | 23.497% |
| Helix BioMedix, Inc. | -1.05 Million USD | -139.594% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 33.746% |
| BioStem Technologies, Inc. | -8.48 Million USD | 70.173% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -473.272% |
| LadRx Corporation | 400.44 Thousand USD | 731.862% |
| Cell Source, Inc. | -5.32 Million USD | 52.45% |
| Regen BioPharma, Inc. | 1.02 Million USD | 347.213% |
| Regen BioPharma, Inc. | 1.02 Million USD | 347.213% |
| NovAccess Global Inc. | -4.76 Million USD | 46.946% |
| Affymax, Inc. | -14.42 Million USD | 82.458% |
| Itoco Inc. | -1.86 Million USD | -35.38% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 43.045% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -51.603% |
| Mobile Lads Corp. | -2.26 Million USD | -11.795% |
| CytoDyn Inc. | -49.84 Million USD | 94.923% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -3101.507% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1009.14% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -168.738% |
| SYBLEU INC | -180.3 Thousand USD | -1303.323% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -56.891% |
| International Stem Cell Corporation | -131 Thousand USD | -1831.486% |
| Bioxytran, Inc. | -4.28 Million USD | 40.882% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -4562.159% |
| Cardax, Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 94.737% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -19.69% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -224.022% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 20.131% |
| Neutra Corp. | -233.46 Thousand USD | -983.78% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 87.53% |
| PureTech Health plc | -65.69 Million USD | 96.149% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 88.102% |
| IXICO plc | -1.17 Million USD | -114.792% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 74.511% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 95.571% |
| CSL Limited | 2.64 Billion USD | 100.096% |
| Cellectis S.A. | -103.17 Million USD | 97.548% |